Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice

Heart

Volumn 92, Issue 10, 2006, Pages 1484-1489

  Heer, Tobias ^a   Zeymer, U ^a   Juenger, C ^a   Gitt, A K ^a   Wienbergen, H ^a   Zahn, R ^b   Gottwik, M ^b   Senges, J ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA;

AGED; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STROKE; SURVIVAL RATE; TRANSIENT ISCHEMIC ATTACK;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750041069     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.085456     Document Type: Article

References (23)

1. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
2. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-65.
3. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2003;42:1-6.
4. Brener SJ, Barr LA, Burchenal JE, et al. Randomised, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardialinfarction: ReoPro and Primary PICA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41.
5. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
6. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
7. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
8. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction. The controlled Abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Circulation 2003;108:1316-23.
9. Antoniucci D, Rodriguez A, Hempel A, et al. A randomised trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42:1879-85.
10. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomised trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004;109:1704-6.
11. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003;42:1886-9.
12. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
13. Wienbergen H, Gilt AK, Schiele R, et al. Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographs changes (results of the acute coronary syndromes (ACOS) registry). Am J Cardiol 2004;93:1543-6.
14. Lorenz H, Jünger C, Seidl K, et al. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction? Eur Heart J 2005;26:1078-85.
15. Montalescot G, Barragan P, Wittenberg O, et al. Three-year follow-up after primary stenting with or without abciximab in acute myocardial infarction (the ADMIRAL trial) [abstract]. Circulation 2002;106(Suppl II):332-3.
16. Brener SJ, Ellis SG, Schneider J, et al. Abciximab-facilitated percutaneous coronary intervention and long-term survival: a prospective single-center registry. Eur Heart J 2003;24:630-8.
17. Heer T, Schiele R, Schneider S, et al. Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol 2002;89:511-7.
18. Barren HV, Bowlby U, Breen T, et al. Use of reperfusion therapy for acute myocardial infarction in the United States. Circulation 1998;97:1150-6.
19. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjuncrive therapy to reperfusion in acute ST-segment elevation myocardial infarction. JAMA 2005;293:1759-65.
20. Neumann F-J, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-701.
21. Lee CW, Moon D-H, Hong M-K, et al. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:1243-5.
22. Neumann F-J, Zohlnhofer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-6.
23. Zahn R, Fraiture B, Siegler KE, et al. Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center. Z Kardiol 2003;92:438-44.